Opens in a new tab or window Geographic atrophy (GA) progressed more often in patients with better baseline vision and those with lesions closer to the foveal center, according to a study that ...

The updated label allows physicians to prescribe Izervay without a limitation on duration for patients with geographic ...

US FDA approves expanded label for Astellas’ Izervay for the treatment of geographic atrophy: Tokyo Friday, February 14, 2025, 09:00 Hrs [IST] Astellas Pharma Inc., a global lif ...

The Food and Drug Administration (FDA) has expanded the labeling for Izervay™ (avacincaptad pegol intravitreal solution) to include longer-term ...

For technical reasons, the English full text will be published approximately two weeks after the German print edition has been published. Zentrum für Augenheilkunde, Cologne Image Reading Center ...

IZERVAY dosing approved beyond 12 monthsTOKYO, Feb. 12, 2025 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Ok ...

Astellas Pharma seeks Japanese conditional approval of avacincaptad pegol intravitreal solution to treat geographic atrophy: Tokyo Thursday, February 6, 2025, 09:00 Hrs [IST] Aste ...

PulseSight Therapeutics SAS, an ophthalmology biotech company developing disruptive non-viral vectorized therapies with minimally-invasive delivery technology, today announces the first close of its ...

Enlargement of geographic atrophy from first diagnosis to end of life. JAMA Ophthalmol. 2021;139(7):743–750. 4 Lundeen EA, Saydah S, Ehrlich J, Saaddine J. Self-reported vision impairment and ...

For technical reasons, the English full text will be published approximately two weeks after the German print edition has been published.

Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced the U.S. Food and Drug Administration (FDA) approved expanded U.S. Prescribing information for IZERVAY™ ...